SynthesisBMC medicine2022
Identifying and ranking causal biochemical biomarkers for breast cancer: a Mendelian randomisation study.
Synthesis in BMC medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Applying Bayesian Multivariable Mendelian Randomisation to Prioritise Candidate Causal Traits From High-Dimensional Data: Illustration From Estimation of the Effect of Maternal Metabolites on Offspring Birthweight.Genetic epidemiology · 2026Article
- BreastSubtypeR: a unified R/Bioconductor package for intrinsic molecular subtyping in breast cancer research.NAR genomics and bioinformatics · 2025Article
- Machine learning algorithms predict breast cancer incidence risk: a data-driven retrospective study based on biochemical biomarkers.BMC cancer · 2025Article
- Mendelian randomization analysis of modifiable risk factors for breast cancer.Discover oncology · 2025Review
- Identifying causal relationships between 35 blood and urine biomarkers and urologic cancers: MR-meta combined with Bayesian colocalization Mendelian randomization analysis.Discover oncology · 2024Article
- Obesity-Dependent Association of the rs10454142Biomedicines · 2024Article
- Breast Cancer Screening and Prophylactic Mastectomy for High-Risk Women in Romania.Medicina (Kaunas, Lithuania) · 2024Review
- Sex-Hormone-Binding Globulin Gene Polymorphisms and Breast Cancer Risk in Caucasian Women of Russia.International journal of molecular sciences · 2024Article
- Construction of a nomogram model for predicting the outcome of debulking surgery for ovarian cancer on the basis of clinical indicators.Frontiers in oncology · 2024Review
- Implications of hormonal carcinogenesis for transgender and gender-diverse people undergoing gender-affirming hormone therapy: an up-to-date review.BMJ oncology · 2024Review
- Causal Effects of Blood Metabolites and Obstructive Sleep Apnea: A Mendelian Randomization Study.Current neurovascular research · 2024Article
- Genetic effect of metformin use on risk of cancers: evidence from Mendelian randomization analysis.Diabetology & metabolic syndrome · 2023Article
- Causal pathways linking polycystic ovary syndrome to distinct breast cancer subtypes through mediator factors: a multivariable mendelian randomization analysis.Journal of ovarian research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundOnly a few of the 34 biochemical biomarkers measured in the UK Biobank (UKB) have been associated with breast cancer, with many associations suffering from possible confounding and reverse causation. This study aimed to screen and rank all UKB biochemical biomarkers for possible causal relationships with breast cancer.
methodsWe conducted two-sample Mendelian randomisation (MR) analyses on ~420,000 women by leveraging summary-level genetic exposure associations from the UKB study (n = 194,174) and summary-level genetic outcome associations from the Breast Cancer Association Consortium (n = 228,951). Our exposures included all 34 biochemical biomarkers in the UKB, and our outcomes were overall, oestrogen-positive, and oestrogen-negative breast cancer. We performed inverse-variance weighted MR, weighted median MR, MR-Egger, and MR-PRESSO for 30 biomarkers for which we found multiple instrumental variables. We additionally performed multivariable MR to adjust for known risk factors, bidirectional MR to investigate reverse causation, and MR Bayesian model averaging to rank the significant biomarkers by their genetic evidence.
resultsIncreased genetic liability to overall breast cancer was robustly associated with the following biomarkers by decreasing importance: testosterone (odds ratio (OR): 1.12, 95% confidence interval (CI): 1.04-1.21), high-density lipoprotein (HDL) cholesterol (OR: 1.08, 95% CI: 1.04-1.13), insulin-like growth factor 1 (OR: 1.08, 95% CI: 1.02-1.13), and alkaline phosphatase (ALP) (OR: 0.93, 95% CI: 0.89-0.98).
conclusionsOur findings support a likely causal role of genetically predicted levels of testosterone, HDL cholesterol, and IGF-1, as well as a novel potential role of ALP in breast cancer aetiology. Further studies are needed to understand full disease pathways that may inform breast cancer prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.